Management of Typhoid Fever

First-Line Treatment Recommendation

• The American College of Physicians recommends azithromycin 500 mg once daily for 7-14 days as the preferred first-line treatment for typhoid fever in adults, particularly given widespread fluoroquinolone resistance in endemic regions 1, 2, 3
• For children, the recommended dose is azithromycin 20 mg/kg/day (maximum 1g/day) for 7-14 days 1, 2

Why Azithromycin Over Fluoroquinolones

• Fluoroquinolone resistance exceeds 70% in South Asia and approaches 96% in some regions, making ciprofloxacin empirically inappropriate for cases originating from these areas 2, 3
• Azithromycin demonstrates superior clinical outcomes with lower risk of treatment failure (OR 0.48) compared to fluoroquinolones 1, 2
• Hospital stays are approximately 1 day shorter with azithromycin (mean difference -1.04 days) 2
• Relapse risk is dramatically lower with azithromycin (OR 0.09) compared to ceftriaxone 1, 3

Treatment Algorithm Based on Clinical Severity

• For uncomplicated typhoid fever, start azithromycin 500 mg once daily orally for 7-14 days 1, 2, 3
• Obtain blood cultures before initiating antibiotics when possible, as they have the highest yield within the first week of symptoms 1, 2
• Expect fever clearance within 4-5 days of appropriate therapy 1, 3

Critical Pitfalls to Avoid

• Do not discontinue antibiotics prematurely - complete the full 7-14 day course even if fever resolves early, as relapse occurs in 10-15% of inadequately treated cases 1, 2
• Never use ciprofloxacin empirically for travel-associated cases from South/Southeast Asia - resistance is nearly universal in these regions 2, 3
• Avoid cefixime as first-line therapy - it has documented treatment failure rates of 4-37.6% and requires mandatory test-of-cure at 1 week if used 2

Management of Complications

• Intestinal perforation occurs in 10-15% of patients when illness duration exceeds 2 weeks 1, 2
• Requires immediate surgical intervention with simple excision and closure, successful in up to 88.2% of cases 1, 2

Monitoring and Expected Response

• Fever should clear within 4-5 days of appropriate antibiotic therapy 1, 3
• Monitor for common azithromycin adverse effects: nausea, vomiting, abdominal pain, and diarrhea 1, 3
• Watch for potential drug interactions with azithromycin, particularly QT-prolonging medications 1, 3
• Complete the full antibiotic course to prevent relapse 1, 2

Prevention Strategies

• Typhoid vaccination is recommended for travelers to endemic areas (Latin America, Asia, Africa), particularly those with moderate to high risk of exposure 4, 3
• Two vaccines are available in the United States: Ty21a oral vaccine and Vi-polysaccharide parenteral vaccine 4
• Important limitations: Vaccination provides only 50-80% protection and does not protect against Salmonella Paratyphi 4, 1, 3
• Hand hygiene and food/water safety precautions remain essential and should not be replaced by vaccination alone 4, 2

Emerging Resistance Concerns

• Always consider local resistance patterns when selecting empiric therapy, as these vary geographically and change over time 2

Management of Uncomplicated Typhoid Fever in Adults (Evidence‑Based Recommendations)

Geographic Resistance Patterns

• In South and Southeast Asia, more than 70 % of Salmonella Typhi isolates are resistant to fluoroquinolones, with some locales reporting resistance rates approaching 96 %【5】.
• Over 70 % of S. Typhi and S. Paratyphi isolates imported into the United Kingdom from Asian countries are fluoroquinolone‑resistant【5】.
• Ciprofloxacin disc diffusion is unreliable; fluoroquinolone susceptibility should be interpreted only when the isolate is also sensitive to nalidixic acid【5】.

Diagnostic Recommendations

• Blood cultures obtained within the first week of symptom onset yield the highest diagnostic sensitivity (approximately 40–80 %)【5】.

First‑Line Empiric Therapy

• Azithromycin 500 mg orally once daily for 7–14 days is recommended as the preferred empiric regimen for adults in regions with high fluoroquinolone resistance (see guideline statements)【5】.

Alternative Treatment Options

• Ceftriaxone remains fully active: all S. Typhi isolates reported to the UK Health Protection Agency in 2006 were susceptible to ceftriaxone【5】.
• Fluoroquinolones may be used only when susceptibility is confirmed and the case is not epidemiologically linked to South/Southeast Asia; in susceptible isolates, fever clears in < 4 days with cure rates >96 %【5】.

Pitfalls to Avoid

• Cefixime is associated with high treatment‑failure rates (4 %–37.6 %) and a 13‑fold higher risk of clinical failure compared with fluoroquinolones (RR ≈ 13.4)【5】.
• The Widal serologic test lacks adequate sensitivity and specificity and should not be used for diagnosis【5】.
• New rapid serologic assays (Typhidot, Tubex) have produced mixed performance results and cannot replace culture‑based diagnosis【5】.

Treatment Duration and Relapse Prevention

• A complete 7–14‑day antimicrobial course is required even after fever resolution to minimise relapse risk【5】.
• Reported relapse rates after adequate therapy are <5 % for fluoroquinolones, <8 % for ceftriaxone, and <3 % for azithromycin【5】.

Monitoring for Severe Complications

• Intestinal perforation occurs in 10–15 % of patients whose illness extends beyond two weeks; prompt surgical excision and closure is successful in approximately 88 % of cases【5】.